Table 2 Patient characteristics at prostate cancer diagnosis.

From: DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance

Characteristic

All patients

Low-risk

Intermediate-risk

Patients

558

283

275

Age (yr), median (IQR)

65 (61–70)

64 (59–68)

67 (63–70)

PSA (ng/ml), n (%)

   ≤6

237 (42)

173 (61)

64 (23)

   >6 and ≤10

228 (41)

110 (39)

118 (43)

   >10 and ≤20

93 (17)

0

93 (34)

Prostate volume (ml), median (IQR)

41 (30–56)

41 (30–53)

42 (31–58)

   Missing

52 (9)

34 (12)

18 (7)

PSA density (ng/ml/cm3), median (IQR)

0.16 (0.11–0.23)

0.13 (0.09–0.19)

0.19 (0.13–0.27)

   Missing

52 (9)

34 (12)

18 (7)

Gleason grade groupa, n (%)

   1

382 (68)

283 (100)

99 (36)

   2

176 (32)

0

176 (64)

Gleason grade groupb, n (%)

   1

230 (41)

152 (54)

78 (28)

   2

257 (46)

102 (36)

155 (56)

   3

25 (4)

6 (2)

19 (7)

   4

13 (2)

4 (1)

9 (3)

   5

3 (1)

0

3 (1)

   Missing

30 (5)

19 (7)

11 (4)

MRI outcome

   No lesion

57 (10)

32 (11)

25 (9)

   3

97 (17)

53 (19)

44 (16)

   4

235 (42)

101 (36)

134 (49)

   5

79 (14)

32 (11)

47 (17)

   Missing

90 (16)

65 (23)

25 (9)

Clinical T stage, n (%)

   cT0/pT1

406 (73)

215 (76)

191 (69)

   cT2

152 (27)

68 (24)

84 (31)

CAPRA scorec, n (%)

   0–2

325 (58)

278 (98)

47 (17)

   3–5

226 (41)

0

226 (82)

   Missing

7 (1)

5 (2)

2 (1)

Diagnostic procedure type, n (%)

   Biopsy

460 (82)

225 (80)

235 (85)

   TURP

98 (18)

58 (20)

40 (15)

Positive biopsy cores, n (%)

2.0 (1.0–4.0)

2.0 (1.0–2.0)

3.0 (1.0–4.0)

   Missing

5 (1)

3 (1)

2 (1)

Percentage of positive biopsy cores (%), median (IQR)

20 (10–40)

17 (10–25)

30 (17–50)

   Missing

7 (1)

5 (2)

2 (1)

Maximum tumour extent in biopsy cores (mm), median (IQR)

4.0 (2.0–7.0)

3.0 (1.3–5.0)

5.0 (2.8–8.0)

   Missing

14 (3)

12 (4)

2 (1)

  1. Due to rounding the numbers may not sum to 100%.
  2. CAPRA Cancer of the Prostate Risk Assessment, IQR interquartile range, MRI magnetic resonance imaging, PIRADS Prostate Imaging Reporting and Data System, PSA prostate-specific antigen, TURP transurethral resection of the prostate.
  3. aRoutine Gleason scoring performed according to the 2005 or 2014 International Society of Urological Pathology guidelines.
  4. bCentrally reviewed Gleason scoring performed according to the 2014 International Society of Urological Pathology guidelines.
  5. cWhen computing CAPRA score for patients diagnosed with TURP, the percentage of positive biopsies was replaced by the tumour percentage in the TURP specimen; specifically, 0 points were assigned for <5% tumour and 1 point was assigned for ≥5% tumour. Computation of CAPRA score was performed using routinely assessed Gleason scores.
Back to article page